Table 1.
treatment strategy | TMZ | SMI APNG | SMI MGMT | ||
---|---|---|---|---|---|
standard TMZ | constant dose days 1–5 | none | none | ||
rest days 6–28 | |||||
optimal TMZ | high dose days 1, 3 and 5 | none | none | ||
low dose days 2 and 4 | |||||
rest days 6–28 | |||||
cell phenotype | APNG−/MGMT− | A | high dose days 1, 3 and 5 | days 1–5 | days 1 and 5 |
low dose days 2 and 4 | |||||
rest days 6–28 | |||||
APNG+/MGMT− | B | high dose days 1, 3 and 5 | days 1–5 | days 2, 3 and 4 | |
low dose days 2 and 4 | |||||
rest days 6–28 | |||||
APNG−/MGMT+ | C | high dose days 1, 3 and 5 | days 1–5 | days 1, 2, 3 and 4 | |
low dose days 2 and 4 | |||||
rest days 6–28 | |||||
APNG+/MGMT+ | D | high dose days 1, 3 and 5 | days 1–5 | days 1–5 | |
low dose days 2 and 4 | |||||
rest days 6–28 |